arrow
S

Stephanie L. Graff

brown university
H指数:21
被引数:3,217

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world patient experiences in HR+/HER2- metastatic breast cancer: a study of symptom and side effect reporting by patients and physicians

HR+/HER2-转移性乳腺癌的实世界患者体验:一项关于患者和医生症状及副作用报告的研究

2026-11-090
OAAI
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy

III期postMONARCH试验中,阿贝西利联合氟维司群与安慰剂联合氟维司群治疗既往接受过CDK4/6抑制剂联合内分泌治疗后进展的HR+、HER2-晚期乳腺癌的总体生存率

2026-10-240
OA
Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer

HER2低表达、HER2超低表达和HER2缺失型男性乳腺癌的分子和免疫图谱分析

Breast
IF7.9
2026-08-010
PRE
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers

年轻BRCA携带者在孕期被诊断患有乳腺癌后,再次怀孕的安全性

2025-08-130
OAAI
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis

真实世界中NATALEE和monarchE符合入组条件的HR+/HER2−早期乳腺癌人群的特征:一项基于美国电子健康记录数据库的分析

2025-06-010
OA
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2-early breast cancer

真实世界中HR+/HER2-早期乳腺癌患者接受辅助内分泌治疗的复发风险和治疗结局

BREAST
IF7.9
2025-06-010
OAAI
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

TROPION-Breast05:一项关于Dato-DXd联合或不联合durvalumab与化疗联合pembrolizumab治疗PD-L1高表达局部复发不可手术或转移性三阴性乳腺癌的随机III期研究

2025-04-170
OA
Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)

在 monarchE 试验中,ctDNA 检测在辅助阿贝西利联合内分泌治疗(ET)于 HR+/HER2-、淋巴结阳性、高危早期乳腺癌(EBC)中的预后价值

BREAST
IF7.9
2025-02-010
OAAI
Prognostic variables for risk of recurrence in patients (pts) with HR+/HER2-early breast cancer (EBC) using data from the NATALEE trial: a machine learning (ML) model-based analysis

HR+/HER2-早期乳腺癌(EBC)患者复发风险的预后变量:基于NATALEE试验数据的机器学习(ML)模型分析

BREAST
IF7.9
2025-02-010
OAAI
Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial

monarchE试验中HR⁺、HER2⁻、淋巴结阳性、高危早期乳腺癌(EBC)患者原发肿瘤的基因组学和转录组学分析

BREAST
IF7.9
2025-02-010
OAAI
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines

[18F]FDG PET/CT在非特殊类型浸润性乳腺癌患者中的作用: 文献回顾和指南比较

BREAST
IF7.9
2024-12-011
OAAI